Paper Search Console

Home Search Page Alphabetical List About Contact

Journal Title

Title of Journal: Breast Cancer Res Treat

Search In Journal Title:

Abbravation: Breast Cancer Research and Treatment

Search In Journal Abbravation:


Springer US

Search In Publisher:



Search In DOI:



Search In ISSN:
Search In Title Of Papers:

Variability in hormone and growth factor receptor expression in primary versus recurrent, metastatic, and post-neoadjuvant breast carcinoma

Authors: Mark N. Jabbour, Cleo Y. Massad, Fouad I. Boulos,

Publish Date: 2012/04/08
Volume: 135, Issue:1, Pages: 29-37
PDF Link


The introduction of selective molecular targeted therapy, specifically tamoxifen and trastuzumab, has significantly altered the clinical behavior of breast carcinoma. Several questions remain, however, regarding potential phenotypic drifts in estrogen receptor (ER), progesterone receptor (PR), and epidermal growth factor receptor (Her-2/neu) expression between the primary and metastatic site. Whether patients should be tested for ER, PR, and Her-2/neu expression in the nodal or distant metastatic site, local recurrence and following neoadjuvant therapy, and whether this has an effect on prognosis remains elusive. A review of 45 studies addressing ER, PR, and Her-2/neu expression in lymph node metastasis, distant metastasis, local recurrence, and post-neoadjuvant therapy revealed the following average phenotypic drift in ER, PR, and Her-2/neu expression, respectively: 13.1 % (median = 10.0 %), 13.8 % (median = 16.0 %), and 7.7 % (median = 5.0 %) for lymph node metastasis; 21.8 % (median = 19.5 %), 30.8 % (median = 33.5 %), and 7.6 % (median = 6.1 %) for distant metastasis; 19.8 % (median = 13.4 %), 27.1 % (median = 28.6 %), and 6.6 % (median = 1.6 %) for local recurrence; and 12.9 % (median = 8.0 %), 32.0 % (median = 20.0 %), and 8.9 % (median = 0 %) post-neoadjuvant therapy. The above findings support the notion of re-evaluating ER, PR, and Her-2/neu expression in distant metastasis, lymph node metastasis and to a lesser extent local recurrence. The effects of neoadjuvant therapy on receptor expression are more pronounced for PR, which may have a prognostic role in therapy efficacy.



Search In Abstract Of Papers:
Other Papers In This Journal:

  1. Variability in hormone and growth factor receptor expression in primary versus recurrent
  2. Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage
  3. Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort
  4. Molecular imaging with a fluorescent antibody targeting carbonic anhydrase IX can successfully detect hypoxic ductal carcinoma in situ of the breast
  5. Feature extraction via composite scoring and voting in breast cancer
  6. Reactive oxygen species induce phosphorylation of serine 118 and 167 on estrogen receptor alpha
  7. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer
  8. Bcl-2 expression correlates with lymphovascular invasion and long-term prognosis in breast cancer
  9. Diagnosis and management of primary breast sarcoma
  10. Recurrent read-through fusion transcripts in breast cancer
  11. Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial
  12. Accuracy of magnetic resonance in suspicious breast lesions: a systematic quantitative review and meta-analysis
  13. Impact of carpal tunnel syndrome surgery on women with breast cancer-related lymphedema
  14. A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer
  15. Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial
  16. Body weight and risk of breast cancer in BRCA1/2 mutation carriers
  17. Molecular epidemiologic features of inflammatory breast cancer: a comparison between Egyptian and US patients
  18. Patterns of nodal staging during breast conservation surgery in the medicare patient: will the ACOSOG Z0011 trial change the pattern of care?
  19. Tumor angiogenesis as prognostic and predictive marker for chemotherapy dose-intensification efficacy in high-risk breast cancer patients within the WSG AM-01 trial
  20. CYP1B1 and predisposition to breast cancer in Poland
  21. Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized
  22. Focused antibody response in plasma cell-infiltrated non-medullary (NOS) breast cancers
  23. The effect of delays in treatment for breast cancer metastasis on survival
  24. Correlation of HER2
  25. TMEM33: a new stress-inducible endoplasmic reticulum transmembrane protein and modulator of the unfolded protein response signaling
  26. HER3
  27. Metformin and breast cancer risk: a meta-analysis and critical literature review
  28. XRCC2 Arg188His polymorphism is not directly associated with breast cancer risk: evidence from 37

Search Result:

Help video to use 'Paper Search Console'